Andrew MBA - Nukkleus Chief Officer
| NUKKW Stock | 0.03 0.00 0.000003% |
Executive
Andrew MBA is Chief Officer of Nukkleus
| Age | 43 |
| Address | 525 Washington Boulevard, Jersey City, NJ, United States, 07310 |
| Phone | 212-791-4663 |
| Web | https://www.nukk.com |
Nukkleus Management Efficiency
The company has return on total asset (ROA) of (1.1502) % which means that it has lost $1.1502 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.7499) %, meaning that it generated substantial loss on money invested by shareholders. Nukkleus' management efficiency ratios could be used to measure how well Nukkleus manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -1.48 in 2024. Return On Capital Employed is likely to climb to -1.12 in 2024. At this time, Nukkleus' Total Assets are fairly stable compared to the past year. Total Current Assets is likely to climb to about 4.5 M in 2024, whereas Non Currrent Assets Other are likely to drop (13.9 M) in 2024.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Ricardo Alvarez | Merit Medical Systems | N/A | |
| Jim Soutter | Hudson Pacific Properties | N/A | |
| Malik Ducard | 51 | ||
| JoAnne Alkire | Merit Medical Systems | N/A | |
| Jeremy King | 55 | ||
| Jeff Douglass | Weyco Group | 42 | |
| DeAnna Osteen | Weyco Group | N/A | |
| Erik Thoreen | Hudson Pacific Properties | N/A | |
| Paul Daniel | Acco Brands | 58 | |
| Julia Donnelly | 41 | ||
| Daniel Walbrun | Hudson Pacific Properties | N/A | |
| Ryan Karchner | Hudson Pacific Properties | N/A | |
| Juan DiazCartelle | Microbot Medical | 48 | |
| Brad Cleveringa | Hudson Pacific Properties | N/A | |
| Mark Butler | Merit Medical Systems | N/A | |
| Eunice Wong | Hudson Pacific Properties | N/A | |
| Harout Diramerian | Hudson Pacific Properties | 49 | |
| Doniel Sutton | 50 | ||
| Wanjiku JD | 53 | ||
| Sarah Comstock | Merit Medical Systems | N/A | |
| Philip Campbell | AMCON Distributing | 62 | |
Management Performance
| Return On Equity | -0.75 | ||||
| Return On Asset | -1.15 |
Nukkleus Leadership Team
Elected by the shareholders, the Nukkleus' board of directors comprises two types of representatives: Nukkleus inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Nukkleus. The board's role is to monitor Nukkleus' management team and ensure that shareholders' interests are well served. Nukkleus' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Nukkleus' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jamal Khurshid, COO Director | ||
| Emil Assentato, CEO and Presidentident | ||
| Menachem Shalom, CEO Director | ||
| Andrew MBA, Chief Officer | ||
| Shawn Dilkes, Chief Officer |
Nukkleus Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Nukkleus a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.75 | ||||
| Return On Asset | -1.15 | ||||
| Profit Margin | (2.53) % | ||||
| Operating Margin | (7.94) % | ||||
| Current Valuation | 330.32 M | ||||
| Number Of Shares Shorted | 15.1 K | ||||
| Price To Sales | 224.73 X | ||||
| Revenue | 16.22 M | ||||
| EBITDA | (1.49 M) | ||||
| Net Income | (11.85 M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Nukkleus Stock Analysis
When running Nukkleus' price analysis, check to measure Nukkleus' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nukkleus is operating at the current time. Most of Nukkleus' value examination focuses on studying past and present price action to predict the probability of Nukkleus' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nukkleus' price. Additionally, you may evaluate how the addition of Nukkleus to your portfolios can decrease your overall portfolio volatility.